Clinical trials of Russia’s first medical exoskeleton have begun in a Moscow hospital, marking the latest step in the Skolkovo-backed innovation’s battle to reach the market.
A patient at the Pirogov Center testing out ExoAtlet's exoskeleton. Photo: ExoAtlet
The exoskeleton, produced by Skolkovo resident ExoAtlet, is being tested by a group of volunteers who are paralyzed from the waist down at the N.I. Pirogov National Medical Surgical Center.
“This is a very important transition for us from lab testing and working with a few pilots to large-scale trials on a broad audience,” said Ekaterina Bereziy, a co-founder of ExoAtlet and its development director.
“At the clinic there are patients with various characteristics, with different injuries, of differing height, weight, even temperament. Each has his or her own wishes and fears. So here we can see the full range of real-life applications for ExoAtlet. For us this is a very important field study,” she added.
ExoAtlet is the first company in Russia to deal with exoskeletons and has patented its technology.
Its medical-use model, known as ExoAtlet-Med, is to support movement for people with restricted limb function and rehabilitation for lower-limb trauma victims. It is designed to help overcome paralysis caused by cerebral apoplexy or spinal cord injury. It could also benefit sufferers of cerebral palsy and similar diseases.
Seven hundred people volunteered to try out the ExoAtlet innovation, but doctors whittled the list down to just a few people to undergo two weeks of intensive training, Bereziy said.
“Here we’ve found support and high levels of interest that are very important for us,” she responded when asked why the Pirogov Center was chosen for the clinical trials.
Despite the short duration of the training courses, the trials will take months to get through, she added.
“We don’t plan to complete our trials in a month, two months or even six – we think this will take at least a year,” Bereziy said.
Photo: ExoAtlet
But the ExoAtlet team won’t let the trial slow their attempts to start generating revenue: “We’re taking the next step in parallel with the trials: We plan to start sales of the exoskeletons for private individuals, and we really hope to complete our first sales by the New Year,” she said.
The doctors, meanwhile, said the technology could be pivotal in the history of spinal injury rehabilitation.
“Roboticized mechanotherapy is one of the leading and actively developing areas of modern rehabilitation,” said Vadim Daminov, the Pirogov Center’s chief rehabilitation therapist. “We hope that thanks to the data that we can collect from the clinical trials of the ExoAtlet exoskeleton, we’ll be able to take the rehab process of spinal cord injury patients to a whole new level.”
When it hits the market, the exoskeleton is expected to retail for about 1.5 million rubles, a price that won’t change despite the weakening currency, Bereziy said.
The clinical trials come almost exactly a year after ExoAtlet joined the Skolkovo ecosystem as a resident of the IT cluster.
“One of Skolkovo’s functions as an innovation center is the acceleration of breakthrough ideas to products on the market,” said Albert Yefimov, Skolkovo’s chief roboticist. “And there’s no doubt that the exoskeleton produced by the ExoAtlet team is a true breakthrough solution. With this project [ExoAtlet], we’ve focused specifically on the acceleration aspect. Just over a year ago the team demonstrated a prototype that was barely usable, but now ExoAtlet has reached the clinical trials phase. The speed of this project’s developed has been simply phenomenal,” Yefimov added.